Scaffold proteins LACK and TRACK as potential drug targets in kinetoplastid parasites: Development of inhibitors

Nir Qvit, Deborah Schechtman, Darlene Aparecida Pena, Denise Aparecida Berti, Chrislaine Oliveira Soares, Qianqian Miao, Liying Liang, Lauren A. Baron, Christian Teh-Poot, Pedro Martínez-Vega, Maria Jesus Ramirez-Sierra, Eric Churchill, Anna D. Cunningham, Andrey V. Malkovskiy, Nancy A. Federspiel, Fabio Cesar Gozzo, Ana Claudia Torrecilhas, Maria Julia Manso Alves, Armando Jardim, Ndao MomarEric Dumonteil, Daria Mochly-Rosen

Research output: Contribution to journalArticlepeer-review

11 Scopus citations

Abstract

Parasitic diseases cause ~500,000 deaths annually and remain a major challenge for therapeutic development. Using a rational design based approach, we developed peptide inhibitors with anti-parasitic activity that were derived from the sequences of parasite scaffold proteins LACK (Leishmania's receptor for activated C-kinase) and TRACK (Trypanosoma receptor for activated C-kinase). We hypothesized that sequences in LACK and TRACK that are conserved in the parasites, but not in the mammalian ortholog, RACK (Receptor for activated C-kinase), may be interaction sites for signaling proteins that are critical for the parasites' viability. One of these peptides exhibited leishmanicidal and trypanocidal activity in culture. Moreover, in infected mice, this peptide was also effective in reducing parasitemia and increasing survival without toxic effects. The identified peptide is a promising new anti-parasitic drug lead, as its unique features may limit toxicity and drug-resistance, thus overcoming central limitations of most anti-parasitic drugs.

Original languageEnglish
Pages (from-to)74-84
Number of pages11
JournalInternational Journal for Parasitology: Drugs and Drug Resistance
Volume6
Issue number1
DOIs
StatePublished - 1 Apr 2016
Externally publishedYes

Bibliographical note

Publisher Copyright:
© 2016 The Authors.

Funding

This work was supported by the National Institutes of Health ( TW008781-01C-IDEA and SPARK to NQ) and ( AI078505 to DM-R). The funders had no role in the study design, data collection and analysis, decision to publish or preparation of the manuscript. The authors declare that there are no conflicts of interest. We thank Dr. Ben Kelly from Louisiana State University for providing antibodies. We thank Dr. Silvia RB Uliana from The University of São Paulo for carrying out initial studies.

FundersFunder number
National Institutes of HealthTW008781-01C-IDEA, AI078505
National Heart, Lung, and Blood InstituteR01HL052141

    Keywords

    • Chagas disease
    • LACK
    • Leishmaniasis
    • Peptide
    • Scaffold protein
    • TRACK

    Fingerprint

    Dive into the research topics of 'Scaffold proteins LACK and TRACK as potential drug targets in kinetoplastid parasites: Development of inhibitors'. Together they form a unique fingerprint.

    Cite this